Proposal for effective treatment of Shiga toxin-producing Escherichia coli infection in mice

Muhammad Yunus Amran, Jun Fujii, Glynis L. Kolling, Sharon Y.A.M. Villanueva, Mosaburo Kainuma, Hideyuki Kobayashi, Hideko Kameyama, Shin ichi Yoshida

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Previously, we reported that minocycline, kanamycin and norfloxacin improved the survival rate in the E32511 model that we developed (FEMS Immunol Med Microbiol 26, 101-108, 1999), but fosfomycin did not. In this study, we investigated the effectiveness of azithromycin (AZM) against Stx2d-producing EHEC O91:H21 strain B2F1 or Stx2c-producing Escherichia coli strain E32511 treated with mitomycin C invivo. Recently, we reported the effectiveness of AZM in our model and AZM strongly inhibited the release of Stx2c from E32511 invitro (PLOS ONE e58959, 2013). However, it was very difficult to completely eliminate E32511 in the mouse feces by treatment with AZM alone. In this report, only AZM or Daio effectively promoted survival of mice infected with B2F1 compared to untreated mice. Furthermore, Daio inhibited the colonization of GFP-expressing B2F1 in the mouse intestine. Similarly, a combination of AZM and Daio in the E32511-infected mice reduced E32511 in the mouse feces and significantly improved survival.

Original languageEnglish
Pages (from-to)57-62
Number of pages6
JournalMicrobial Pathogenesis
Volume65
DOIs
Publication statusPublished - Dec 1 2013

Fingerprint

Shiga-Toxigenic Escherichia coli
Escherichia coli Infections
Azithromycin
Feces
Fosfomycin
Enterohemorrhagic Escherichia coli
Norfloxacin
Minocycline
Kanamycin
Mitomycin
Intestines
Escherichia coli

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Infectious Diseases

Cite this

Amran, M. Y., Fujii, J., Kolling, G. L., Villanueva, S. Y. A. M., Kainuma, M., Kobayashi, H., ... Yoshida, S. I. (2013). Proposal for effective treatment of Shiga toxin-producing Escherichia coli infection in mice. Microbial Pathogenesis, 65, 57-62. https://doi.org/10.1016/j.micpath.2013.09.008

Proposal for effective treatment of Shiga toxin-producing Escherichia coli infection in mice. / Amran, Muhammad Yunus; Fujii, Jun; Kolling, Glynis L.; Villanueva, Sharon Y.A.M.; Kainuma, Mosaburo; Kobayashi, Hideyuki; Kameyama, Hideko; Yoshida, Shin ichi.

In: Microbial Pathogenesis, Vol. 65, 01.12.2013, p. 57-62.

Research output: Contribution to journalArticle

Amran, MY, Fujii, J, Kolling, GL, Villanueva, SYAM, Kainuma, M, Kobayashi, H, Kameyama, H & Yoshida, SI 2013, 'Proposal for effective treatment of Shiga toxin-producing Escherichia coli infection in mice', Microbial Pathogenesis, vol. 65, pp. 57-62. https://doi.org/10.1016/j.micpath.2013.09.008
Amran, Muhammad Yunus ; Fujii, Jun ; Kolling, Glynis L. ; Villanueva, Sharon Y.A.M. ; Kainuma, Mosaburo ; Kobayashi, Hideyuki ; Kameyama, Hideko ; Yoshida, Shin ichi. / Proposal for effective treatment of Shiga toxin-producing Escherichia coli infection in mice. In: Microbial Pathogenesis. 2013 ; Vol. 65. pp. 57-62.
@article{be107304f3694064820fec6c7061babe,
title = "Proposal for effective treatment of Shiga toxin-producing Escherichia coli infection in mice",
abstract = "Previously, we reported that minocycline, kanamycin and norfloxacin improved the survival rate in the E32511 model that we developed (FEMS Immunol Med Microbiol 26, 101-108, 1999), but fosfomycin did not. In this study, we investigated the effectiveness of azithromycin (AZM) against Stx2d-producing EHEC O91:H21 strain B2F1 or Stx2c-producing Escherichia coli strain E32511 treated with mitomycin C invivo. Recently, we reported the effectiveness of AZM in our model and AZM strongly inhibited the release of Stx2c from E32511 invitro (PLOS ONE e58959, 2013). However, it was very difficult to completely eliminate E32511 in the mouse feces by treatment with AZM alone. In this report, only AZM or Daio effectively promoted survival of mice infected with B2F1 compared to untreated mice. Furthermore, Daio inhibited the colonization of GFP-expressing B2F1 in the mouse intestine. Similarly, a combination of AZM and Daio in the E32511-infected mice reduced E32511 in the mouse feces and significantly improved survival.",
author = "Amran, {Muhammad Yunus} and Jun Fujii and Kolling, {Glynis L.} and Villanueva, {Sharon Y.A.M.} and Mosaburo Kainuma and Hideyuki Kobayashi and Hideko Kameyama and Yoshida, {Shin ichi}",
year = "2013",
month = "12",
day = "1",
doi = "10.1016/j.micpath.2013.09.008",
language = "English",
volume = "65",
pages = "57--62",
journal = "Microbial Pathogenesis",
issn = "0882-4010",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Proposal for effective treatment of Shiga toxin-producing Escherichia coli infection in mice

AU - Amran, Muhammad Yunus

AU - Fujii, Jun

AU - Kolling, Glynis L.

AU - Villanueva, Sharon Y.A.M.

AU - Kainuma, Mosaburo

AU - Kobayashi, Hideyuki

AU - Kameyama, Hideko

AU - Yoshida, Shin ichi

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Previously, we reported that minocycline, kanamycin and norfloxacin improved the survival rate in the E32511 model that we developed (FEMS Immunol Med Microbiol 26, 101-108, 1999), but fosfomycin did not. In this study, we investigated the effectiveness of azithromycin (AZM) against Stx2d-producing EHEC O91:H21 strain B2F1 or Stx2c-producing Escherichia coli strain E32511 treated with mitomycin C invivo. Recently, we reported the effectiveness of AZM in our model and AZM strongly inhibited the release of Stx2c from E32511 invitro (PLOS ONE e58959, 2013). However, it was very difficult to completely eliminate E32511 in the mouse feces by treatment with AZM alone. In this report, only AZM or Daio effectively promoted survival of mice infected with B2F1 compared to untreated mice. Furthermore, Daio inhibited the colonization of GFP-expressing B2F1 in the mouse intestine. Similarly, a combination of AZM and Daio in the E32511-infected mice reduced E32511 in the mouse feces and significantly improved survival.

AB - Previously, we reported that minocycline, kanamycin and norfloxacin improved the survival rate in the E32511 model that we developed (FEMS Immunol Med Microbiol 26, 101-108, 1999), but fosfomycin did not. In this study, we investigated the effectiveness of azithromycin (AZM) against Stx2d-producing EHEC O91:H21 strain B2F1 or Stx2c-producing Escherichia coli strain E32511 treated with mitomycin C invivo. Recently, we reported the effectiveness of AZM in our model and AZM strongly inhibited the release of Stx2c from E32511 invitro (PLOS ONE e58959, 2013). However, it was very difficult to completely eliminate E32511 in the mouse feces by treatment with AZM alone. In this report, only AZM or Daio effectively promoted survival of mice infected with B2F1 compared to untreated mice. Furthermore, Daio inhibited the colonization of GFP-expressing B2F1 in the mouse intestine. Similarly, a combination of AZM and Daio in the E32511-infected mice reduced E32511 in the mouse feces and significantly improved survival.

UR - http://www.scopus.com/inward/record.url?scp=84886239396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886239396&partnerID=8YFLogxK

U2 - 10.1016/j.micpath.2013.09.008

DO - 10.1016/j.micpath.2013.09.008

M3 - Article

C2 - 24120399

AN - SCOPUS:84886239396

VL - 65

SP - 57

EP - 62

JO - Microbial Pathogenesis

JF - Microbial Pathogenesis

SN - 0882-4010

ER -